By Lina carolina 
A groundbreaking, incision-free therapeutic approach developed at the University of Virginia (UVA) Health has demonstrated exceptional promise in early-stage investigations for treating cerebral cavernous malformations (CCMs), also known as cavernomas. These often debilitating lesions, characterized by abnormal clusters of blood vessels in the brain, have shown near-complete cessation of growth following treatment with this innovative method. The technique, which leverages focused ultrasound in conjunction with gas-filled microbubbles, represents a potential paradigm shift in the management of these complex neurological conditions, offering a less invasive alternative to existing surgical and radiation-based interventions.
The Science Behind the Breakthrough
The novel technique deploys microscopic, gas-filled bubbles that are precisely propelled by focused ultrasound waves. This controlled energy delivery allows the microbubbles to transiently and safely open the brain’s protective blood-brain barrier. While initially explored as a means to facilitate drug and gene delivery to CCMs, researchers at UVA Health made an unexpected discovery: the focused ultrasound and microbubble combination alone proved remarkably effective in stabilizing and halting the progression of these malformations.
Dr. Richard J. Price, PhD, co-director of UVA Health’s Focused Ultrasound Cancer Immunotherapy Center, described the discovery as a moment of scientific serendipity. "We were looking for something else — performing long-term safety studies of focused ultrasound as a tool for drug and gene delivery to CCMs — when we noticed that CCMs exposed to just focused ultrasound with microbubbles were being stabilized," Dr. Price stated. "After the initial observations, we spent years doing experiments to confirm the effect was real and reproducible." He further expressed optimism about the technique’s potential, noting, "Because the focused ultrasound treatment is relatively simple and non-invasive and the necessary clinical devices are becoming more common, if proven safe in clinical trials, I am hopeful it could eventually become a real treatment option."
Understanding Cerebral Cavernous Malformations (CCMs)
CCMs are vascular malformations that can occur in the brain, spinal cord, and other parts of the body. They are essentially abnormal clusters of dilated, thin-walled blood vessels that can resemble a raspberry. While many individuals with cavernomas remain asymptomatic throughout their lives, a significant portion can experience serious neurological complications. These symptoms can range from debilitating headaches and seizures to muscle weakness, and in severe cases, life-threatening brain hemorrhages.
The prevalence of symptomatic CCMs is estimated to be between 1 in 200 to 1 in 500 individuals. However, many are discovered incidentally during imaging for other conditions. The risk of bleeding from a CCM varies, with estimates suggesting an annual rupture risk of around 0.5% to 2%, which can increase with factors such as lesion location and patient history.
Traditional Treatment Modalities and Their Limitations
Currently, treatment options for CCMs are limited and often carry significant risks. Brain surgery is a primary intervention, particularly when a CCM is identified as being at high risk of causing a dangerous brain bleed. However, neurosurgery inherently involves the risks associated with any major surgical procedure, including infection, bleeding, and damage to surrounding brain tissue. Furthermore, there is a possibility of regrowth of the cavernoma after surgical removal.
Another established treatment is stereotactic radiosurgery, which employs precisely targeted radiation to destroy CCMs. This technique is often considered for lesions that are surgically inaccessible or when surgery is deemed too risky. While effective in reducing the size and bleeding risk of some CCMs, radiosurgery can also lead to collateral damage to healthy brain tissue, potentially causing side effects such as cognitive impairment, radiation necrosis, and secondary tumors in the long term.
UVA’s novel approach offers a compelling alternative by aiming to bypass the risks associated with both surgery and radiation. "UVA’s new approach could offer an alternative that avoids unwanted side effects associated with brain surgery and stereotactic radiosurgery," Dr. Price explained.
Remarkable Efficacy in Preclinical Studies
The efficacy of the focused ultrasound and microbubble treatment has been strikingly demonstrated in laboratory tests. In preclinical studies involving mouse models engineered to develop severe CCMs, the results were profoundly encouraging. "Price and his collaborators were shocked at how well their microbubble treatment performed in lab tests," the original report noted. Specifically, one month post-treatment, the technique successfully halted the growth of an astonishing 94% of CCMs in the treated mice. In stark contrast, untreated CCMs in the same study exhibited a seven-fold increase in size during the same period.
The aggressive nature of CCMs in these mouse models, which grow exponentially, makes the observed response even more significant. "One thing that really stands out is the magnitude of the effect," Dr. Price emphasized. "The mouse models of CCM are much more severe than human CCMs. Mouse CCMs grow exponentially. Yet despite their aggressive nature, CCMs in mice still respond completely to treatment."
Potential for Prophylactic Effects and Broader Applications
Beyond halting existing lesion growth, preliminary findings suggest a potential prophylactic effect of the focused ultrasound and microbubble treatment. In some studies, researchers observed that brain tissue exposed to the treatment was less prone to developing new CCMs in the future. This finding, if translatable to humans, could have profound implications for individuals with genetic predispositions to developing multiple CCMs throughout their lives, often referred to as "familial" CCM patients. "If translated to humans, this prophylactic effect could open the door to treatments for so-called ‘familial’ patients who are genetically predisposed to acquiring multiple new CCMs throughout their lifespan," Dr. Price elaborated.
The current state of the technology also suggests that the focused ultrasound and microbubble approach is viable with existing medical equipment. Simulated treatment plans for patients with CCMs, including those who have already undergone stereotactic radiosurgery, have indicated that the technique can be readily implemented. However, rigorous clinical trials will be essential before the Food and Drug Administration (FDA) would consider approving it for patient use.
The Intriguing Role of Microbubbles Without Drugs
A particularly intriguing aspect of UVA’s innovation is its effectiveness even without the administration of any drugs. For years, scientists have been exploring the potential of focused ultrasound to transiently breach the blood-brain barrier, enabling the targeted delivery of therapeutic agents for conditions like Alzheimer’s disease. While the UVA team initially pursued this drug-delivery avenue for CCMs, the discovery of the standalone efficacy of focused ultrasound with microbubbles has opened new avenues of research.
"One notable aspect of the approach is that it doesn’t involve the use of any drugs," the article highlighted. "Scientists at UVA and elsewhere have been exploring the potential of focused ultrasound to briefly breach the blood-brain barrier — the brain’s natural defenses — to allow the targeted delivery of medications for Alzheimer’s and other conditions. But in both Alzheimer’s and now cavernomas, the use of the sound-propelled microbubbles appears to have dramatic benefits even without drugs — benefits scientists can’t fully explain."
The striking results observed in Alzheimer’s research, utilizing a similar focused ultrasound and microbubble approach, have already propelled several clinical trials into patient testing. Dr. Price and his colleagues are hopeful that the pioneering work on CCMs will similarly catalyze the initiation of human trials in the near future.
Future Directions and Research Investment
The UVA team is actively pursuing a deeper understanding of the mechanisms underlying this observed effect. "We are very interested in understanding what is in the ‘black box’ that somehow connects focused ultrasound to the cessation of mutant cell expansion in the CCMs," Dr. Price stated. This research could potentially unlock new therapeutic strategies. Furthermore, the researchers are revisiting their original focus on drug and gene delivery, considering that the baseline stabilization effect of the ultrasound and microbubbles might now pave the way for complete eradication of lesions when combined with additional therapies. "We are also returning to our original ideas about drug and gene delivery to CCMs. Since the baseline effect stabilizes the lesions, perhaps we can now think of eradicating them entirely with additional therapies," Price mused.
This breakthrough is a testament to UVA Health’s sustained investment in focused ultrasound technology over many years. "This type of discovery is largely an outcome of the investments UVA has made in focused ultrasound technology over the years. There are few other institutions in the world with the critical mass of expertise and infrastructure to allow new discoveries like this," Price acknowledged.
To further advance this critical research, Dr. Price and his collaborator, Petr Tvrdik, PhD, recently secured a significant grant of over $3 million from the National Institutes of Health’s National Cancer Institute. This funding will be instrumental in supporting their ongoing investigations into CCMs.
The Evolution of Focused Ultrasound at UVA Health
UVA Health has been at the forefront of focused ultrasound technology, serving as an early pioneer in its development and application. This deep expertise has fostered a robust research program dedicated to exploring the potential of focused ultrasound across a wide spectrum of medical conditions. The remarkable promise of this technology prompted UVA Health, in collaboration with the Charlottesville-based Focused Ultrasound Foundation, to establish the Focused Ultrasound Cancer Immunotherapy Center, the world’s first dedicated institution focused on advancing the field. This center serves as a hub for innovation, bringing together leading researchers and clinicians to accelerate the translation of focused ultrasound therapies from the laboratory to the patient bedside. The ongoing advancements in CCM treatment exemplify the transformative potential of this commitment to cutting-edge medical research and technology.